AMGEN INC — Director's Dealing 2021

Mar 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2021-03-02

Reporting Person: Johnston Lori A (EVP, HR)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-02	Common Stock	A	5608	—	Acquired	37682	Direct

Footnotes

F1: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 670 RSUs which vest on 5/1/2021; 1,359 RSUs which vest in installments of 669 on 4/27/2021 and 690 on 4/27/2022; 2,030 RSUs which will vest in installments of 669 on 5/3/2021, 670 on 5/3/2022 and 691 on 5/3/2023; 7,799 RSUs which will vest in installments of 2,573 on 11/1/2021, 2,574 on 11/1/2022 and 2,652 on 11/1/2023; and 2,961 RSUs which vest in two installments of 977 on 5/5/2022 and 5/5/2023, and one installment of 1,007 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2: These shares include 561 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.